Effect of a 300 000-IU loading dose of ergocalciferol (vitamin D2) on circulating 1,25(OH)2-vitamin D and fibroblast growth factor-23 (FGF-23) in vitamin D insufficiency

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 2, 2013, Pages 550-556

  Turner, C ^a   Dalton, N ^a   Inaoui, R ^b   Fogelman, I ^b,c   Fraser, W D ^e   Hampson, G ^b,d  

^a EVELINA LONDON CHILDREN S HOSPITAL   (United Kingdom)

^b Osteoporosis Clinic   (United States)

^c GUY S HOSPITAL   (United Kingdom)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; PHOSPHATE;

ADULT; ARTICLE; BIOCHEMISTRY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TREATMENT DURATION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

AGED; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; ERGOCALCIFEROLS; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; POSTMENOPAUSE; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84873623751     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2790     Document Type: Article

References (40)

1. Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P. Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab. 2007;92(4):1415-1423.
2. Avenell A, Gillespie WJ, Gillespie LD, O'Connell D. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev. 2009;(2):CD000227.
3. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med. 2009;169(6):551-561.
4. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab. 2012;97(4):1153-1158.
5. Rosen CJ, Abrams SA, Aloia JF, et al. IOM committee members respond to Endocrine Society vitaminDguideline. J Clin Endocrinol Metab. 2012;97(4):1146-1152.
6. Farrell CJ, Martin S, McWhinney B, Straub I, Williams P, Herrmann M. State-of-the-art vitamin D assays: a comparison of automated immunoassays with liquid chromatography-tandem mass spectrometry methods. Clin Chem. 2012;58(3):531-542.
7. Heijboer AC, Blankenstein MA, Kema IP, Buijs MM. Accuracy of 6 routine 25-hydroxyvitamin D assays: influence of vitaminDbinding protein concentration. Clin Chem. 2012;58(3):543-548.
8. Glendenning P, Taranto M, Noble JM, et al. Current assays overestimate 25-hydroxyvitamin D3 and underestimate 25-hydroxyvitamin D2 compared with HPLC: need for assay-specific decision limits and metabolite-specific assays. Ann Clin Biochem. 2006;43 (Pt 1):23-30.
9. Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA. 2010;303(18):1815-1822.
10. Smith H, Anderson F, Raphael H, Maslin P, Crozier S, Cooper C. Effect of annual intramuscular vitamin D on fracture risk in elderly men and women-a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology (Oxford). 2007;46(12): 1852-1857.
11. Beckman MJ, Johnson JA, Goff JP, Reinhardt TA, Beitz DC, Horst RL. The role of dietary calcium in the physiology of vitamin D toxicity: excess dietary vitamin D3 blunts parathyroid hormone induction of kidney 1-hydroxylase. Arch Biochem Biophys. 1995; 319(2):535-539.
12. Prie D, Friedlander G. Reciprocal control of 1,25-dihydroxyvitamin D and FGF23 formation involving the FGF23/Klotho system. Clin J Am Soc Nephrol. 2010;5(9):1717-1722.
13. Raisz LG, Trummel CL, Holick MF, DeLuca HF. 1,25- Dihydroxycholecalciferol: a potent stimulator of bone resorption in tissue culture. Science. 1972;175(4023):768-769.
14. Fraser WD, Durham BH, Berry JL, Mawer EB. Measurement of plasma 1,25 dihydroxyvitamin D using a novel immunoextraction technique and immunoassay with iodine labelled vitamin D tracer. Ann Clin Biochem. 1997;34(Pt 6):632-637.
15. Phinney KW, Bedner M, Tai SS, et al. Development and certification of a standard reference material for vitaminDmetabolites in human serum. Anal Chem. 2012;84(2):956-962.
16. Casetta B, Jans I, Billen J, Vanderschueren D, Bouillon R. Development of a method for the quantification of 1α,25(OH)2-vitamin D3 in serum by liquid chromatography tandem mass spectrometry without derivatization. Eur J Mass Spectrom (Chichester, Eng). 2010;16(1):81-89.
17. Binkley N, Krueger DC, Morgan S, Wiebe D. Current status of clinical 25-hydroxyvitamin D measurement: an assessment of between-laboratory agreement. Clin Chim Acta. 2010;411(23-24): 1976-1982.
18. Romagnoli E, Mascia ML, Cipriani C, et al. Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitaminD2) or cholecalciferol (vitaminD3) in the elderly. J Clin Endocrinol Metab. 2008;93(8):3015-3020.
19. Heaney RP, Recker RR, Grote J, Horst RL, Armas LA. Vitamin D3 is more potent than vitaminD2 in humans. J Clin Endocrinol Metab. 2011;96(3):E447-E452.
20. Holick MF, Biancuzzo RM, Chen TC, et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab. 2008;93(3):677-681.
21. Gordon CM, Williams AL, Feldman HA, et al. Treatment of hypovitaminosis D in infants and toddlers. J Clin Endocrinol Metab. 2008;93(7):2716-2721.
22. Barake M, Daher RT, Salti I, et al. 25-Hydroxyvitamin D assay variations and impact on clinical decision making. J Clin Endocrinol Metab. 2012;97(3):835-843.
23. Duan X, Weinstock-Guttman B, Wang H, et al. Ultrasensitive quantification of serum vitaminDmetabolites using selective solid-phase extraction coupled to microflow liquid chromatography and isotope-dilution mass spectrometry. Anal Chem. 2010;82(6):2488-2497.
24. Clive DR, Sudhaker D, Giacherio D, et al. Analytical and clinical validation of a radioimmunoassay for the measurement of 1,25 dihydroxy vitamin D. Clin Biochem. 2002;35(7):517-521.
25. Strathmann FG, Laha TJ, Hoofnagle AN. Quantification of 1α, 25-dihydroxy vitamin D by immunoextraction and liquid chromatography-tandem mass spectrometry. Clin Chem. 2011;57(9):1279-1285.
26. Hollis BW, Kamerud JQ, Kurkowski A, Beaulieu J, Napoli JL. Quantification of circulating 1,25-dihydroxyvitaminDby radioimmunoassay with 125I-labeled tracer. Clin Chem. 1996;42(4):586-592.
27. Papaioannou A, Kennedy CC, Giangregorio L, et al. A randomized controlled trial of vitamin D dosing strategies after acute hip fracture: no advantage of loading doses over daily supplementation. BMC Musculoskelet Disord. 2011;12:135.
28. Yamaguchi M, Weitzmann MN. High dose 1,25(OH)2D3 inhibits osteoblast mineralization in vitro. Int J Mol Med. 2012;29(5):934-938.
29. Rossini M, Gatti D, Viapiana O, et al. Short-term effects on bone turnover markers of a single high dose of oral vitamin D3. J Clin Endocrinol Metab. 2012;97(4):E622-E626.
30. Quarles LD. Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol. 2012;8(5):276-286.
31. Wesseling-Perry K, Pereira RC, Sahney S, et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int. 2011;79(1):112-119.
32. Imel EA, DiMeglio LA, Hui SL, Carpenter TO, Econs MJ. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab. 2010;95(4):1846-1850.
33. Uzum AK, Salman S, Telci A, Boztepe H, Tanakol R, Alagol F, Ozbey NC. Effects of vitamin D replacement therapy on serum FGF23 concentrations in vitamin D-deficient women in short term. Eur J Endocrinol. 2010;163(5):825-831.
34. Vervloet MG, van Ittersum FJ, Buttler RM, Heijboer AC, Blankenstein MA, ter Wee PM. Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin JAmSoc Nephrol. 2011; 6(2):383-389.
35. Gutierrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009;119(19):2545-2552.
36. Jean G, Bresson E, Terrat JC, et al. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant. 2009;24(3):948-955.
37. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359(6):584-592.
38. Rodriguez-Ortiz ME, Lopez I, Munoz-Castaneda JR, et al. Calcium deficiency reduces circulating levels of FGF23. J Am Soc Nephrol. 2012;23(7):1190-1197.
39. Imel EA, Hui SL, Econs MJ. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res. 2007;22(4):520-526.
40. Wang H, Yoshiko Y, Yamamoto R, et al. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res. 2008;23(6):939-948.